197 related articles for article (PubMed ID: 25139565)
1. Fragment-based identification and optimization of a class of potent pyrrolo[2,1-f][1,2,4]triazine MAP4K4 inhibitors.
Wang L; Stanley M; Boggs JW; Crawford TD; Bravo BJ; Giannetti AM; Harris SF; Magnuson SR; Nonomiya J; Schmidt S; Wu P; Ye W; Gould SE; Murray LJ; Ndubaku CO; Chen H
Bioorg Med Chem Lett; 2014 Sep; 24(18):4546-4552. PubMed ID: 25139565
[TBL] [Abstract][Full Text] [Related]
2. Discovery of selective 4-Amino-pyridopyrimidine inhibitors of MAP4K4 using fragment-based lead identification and optimization.
Crawford TD; Ndubaku CO; Chen H; Boggs JW; Bravo BJ; Delatorre K; Giannetti AM; Gould SE; Harris SF; Magnuson SR; McNamara E; Murray LJ; Nonomiya J; Sambrone A; Schmidt S; Smyczek T; Stanley M; Vitorino P; Wang L; West K; Wu P; Ye W
J Med Chem; 2014 Apr; 57(8):3484-93. PubMed ID: 24673130
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and SAR of new pyrrolo[2,1-f][1,2,4]triazines as potent p38 alpha MAP kinase inhibitors.
Wrobleski ST; Lin S; Hynes J; Wu H; Pitt S; Shen DR; Zhang R; Gillooly KM; Shuster DJ; McIntyre KW; Doweyko AM; Kish KF; Tredup JA; Duke GJ; Sack JS; McKinnon M; Dodd J; Barrish JC; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2008 Apr; 18(8):2739-44. PubMed ID: 18364256
[TBL] [Abstract][Full Text] [Related]
4. Novel series of pyrrolotriazine analogs as highly potent pan-Aurora kinase inhibitors.
Abraham S; Hadd MJ; Tran L; Vickers T; Sindac J; Milanov ZV; Holladay MW; Bhagwat SS; Hua H; Ford Pulido JM; Cramer MD; Gitnick D; James J; Dao A; Belli B; Armstrong RC; Treiber DK; Liu G
Bioorg Med Chem Lett; 2011 Sep; 21(18):5296-300. PubMed ID: 21802948
[TBL] [Abstract][Full Text] [Related]
5. Neuritogenic militarinone-inspired 4-hydroxypyridones target the stress pathway kinase MAP4K4.
Schröder P; Förster T; Kleine S; Becker C; Richters A; Ziegler S; Rauh D; Kumar K; Waldmann H
Angew Chem Int Ed Engl; 2015 Oct; 54(42):12398-403. PubMed ID: 25908259
[TBL] [Abstract][Full Text] [Related]
6. Bis(morpholino-1,3,5-triazine) derivatives: potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase/mammalian target of rapamycin inhibitors: discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor.
Venkatesan AM; Dehnhardt CM; Delos Santos E; Chen Z; Dos Santos O; Ayral-Kaloustian S; Khafizova G; Brooijmans N; Mallon R; Hollander I; Feldberg L; Lucas J; Yu K; Gibbons J; Abraham RT; Chaudhary I; Mansour TS
J Med Chem; 2010 Mar; 53(6):2636-45. PubMed ID: 20166697
[TBL] [Abstract][Full Text] [Related]
7. Structure-based lead identification of ATP-competitive MK2 inhibitors.
Barf T; Kaptein A; de Wilde S; van der Heijden R; van Someren R; Demont D; Schultz-Fademrecht C; Versteegh J; van Zeeland M; Seegers N; Kazemier B; van de Kar B; van Hoek M; de Roos J; Klop H; Smeets R; Hofstra C; Hornberg J; Oubrie A
Bioorg Med Chem Lett; 2011 Jun; 21(12):3818-22. PubMed ID: 21565500
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel 7-azaindoles as PDK1 inhibitors.
Wucherer-Plietker M; Merkul E; Müller TJJ; Esdar C; Knöchel T; Heinrich T; Buchstaller HP; Greiner H; Dorsch D; Finsinger D; Calderini M; Bruge D; Grädler U
Bioorg Med Chem Lett; 2016 Jul; 26(13):3073-3080. PubMed ID: 27217002
[TBL] [Abstract][Full Text] [Related]
9. Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of Tyrosine Threonine Kinase, TTK.
Laufer R; Li SW; Liu Y; Ng G; Lang Y; Feher M; Brokx R; Beletskaya I; Hodgson R; Mao G; Plotnikova O; Awrey DE; Mason JM; Wei X; Lin DC; Che Y; Kiarash R; Madeira B; Fletcher GC; Mak TW; Bray MR; Pauls HW
Bioorg Med Chem Lett; 2016 Aug; 26(15):3562-6. PubMed ID: 27335255
[TBL] [Abstract][Full Text] [Related]
10. Potency switch between CHK1 and MK2: discovery of imidazo[1,2-a]pyrazine- and imidazo[1,2-c]pyrimidine-based kinase inhibitors.
Meng Z; Ciavarri JP; McRiner A; Zhao Y; Zhao L; Reddy PA; Zhang X; Fischmann TO; Whitehurst C; Arshad Siddiqui M
Bioorg Med Chem Lett; 2013 May; 23(10):2863-7. PubMed ID: 23587425
[TBL] [Abstract][Full Text] [Related]
11. Imidazotriazines: Spleen Tyrosine Kinase (Syk) Inhibitors Identified by Free-Energy Perturbation (FEP).
Lovering F; Aevazelis C; Chang J; Dehnhardt C; Fitz L; Han S; Janz K; Lee J; Kaila N; McDonald J; Moore W; Moretto A; Papaioannou N; Richard D; Ryan MS; Wan ZK; Thorarensen A
ChemMedChem; 2016 Jan; 11(2):217-33. PubMed ID: 26381330
[TBL] [Abstract][Full Text] [Related]
12. O-linked triazolotriazines: potent and selective c-Met inhibitors.
Chen F; Wang Y; Ai J; Zhan Z; Lv Y; Liang Z; Luo C; Mei D; Geng M; Duan W
ChemMedChem; 2012 Jul; 7(7):1276-85. PubMed ID: 22539497
[TBL] [Abstract][Full Text] [Related]
13. Discovery and optimization of 2-(4-substituted-pyrrolo[2,3-b]pyridin-3-yl)methylene-4-hydroxybenzofuran-3(2H)-ones as potent and selective ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR).
Tsou HR; MacEwan G; Birnberg G; Grosu G; Bursavich MG; Bard J; Brooijmans N; Toral-Barza L; Hollander I; Mansour TS; Ayral-Kaloustian S; Yu K
Bioorg Med Chem Lett; 2010 Apr; 20(7):2321-5. PubMed ID: 20188552
[TBL] [Abstract][Full Text] [Related]
14. Structure-based optimization of morpholino-triazines as PI3K and mTOR inhibitors.
Poulsen A; Williams M; Nagaraj HM; William AD; Wang H; Soh CK; Xiong ZC; Dymock B
Bioorg Med Chem Lett; 2012 Jan; 22(2):1009-13. PubMed ID: 22197143
[TBL] [Abstract][Full Text] [Related]
15. Structure-based design and synthesis of novel macrocyclic pyrazolo[1,5-a] [1,3,5]triazine compounds as potent inhibitors of protein kinase CK2 and their anticancer activities.
Nie Z; Perretta C; Erickson P; Margosiak S; Lu J; Averill A; Almassy R; Chu S
Bioorg Med Chem Lett; 2008 Jan; 18(2):619-23. PubMed ID: 18055206
[TBL] [Abstract][Full Text] [Related]
16. Discovery and initial SAR of inhibitors of interleukin-1 receptor-associated kinase-4.
Powers JP; Li S; Jaen JC; Liu J; Walker NP; Wang Z; Wesche H
Bioorg Med Chem Lett; 2006 Jun; 16(11):2842-5. PubMed ID: 16563752
[TBL] [Abstract][Full Text] [Related]
17. 2-Aminopyridine-Based Mitogen-Activated Protein Kinase Kinase Kinase Kinase 4 (MAP4K4) Inhibitors: Assessment of Mechanism-Based Safety.
Dow RL; Ammirati M; Bagley SW; Bhattacharya SK; Buckbinder L; Cortes C; El-Kattan AF; Ford K; Freeman GB; Guimarães CRW; Liu S; Niosi M; Skoura A; Tess D
J Med Chem; 2018 Apr; 61(7):3114-3125. PubMed ID: 29570292
[TBL] [Abstract][Full Text] [Related]
18. Discovery of a novel series of potent MK2 non-ATP competitive inhibitors using 1,2-substituted azoles as cis-amide isosteres.
Xiao D; Zhu X; Sofolarides M; Degrado S; Shao N; Rao A; Chen X; Aslanian R; Fossetta J; Tian F; Trivedi P; Lundell D; Palani A
Bioorg Med Chem Lett; 2014 Aug; 24(15):3609-13. PubMed ID: 24913714
[TBL] [Abstract][Full Text] [Related]
19. In vivo and in vitro SAR of tetracyclic MAPKAP-K2 (MK2) inhibitors. Part I.
Revesz L; Schlapbach A; Aichholz R; Feifel R; Hawtin S; Heng R; Hiestand P; Jahnke W; Koch G; Kroemer M; Möbitz H; Scheufler C; Velcicky J; Huppertz C
Bioorg Med Chem Lett; 2010 Aug; 20(15):4715-8. PubMed ID: 20594847
[TBL] [Abstract][Full Text] [Related]
20. Stepwise Evolution of Fragment Hits against MAPK Interacting Kinases 1 and 2.
Kwiatkowski J; Liu B; Pang S; Ahmad NHB; Wang G; Poulsen A; Yang H; Poh YR; Tee DHY; Ong E; Retna P; Dinie N; Kwek P; Wee JLK; Manoharan V; Low CB; Seah PG; Pendharkar V; Sangthongpitag K; Joy J; Baburajendran N; Jansson AE; Nacro K; Hill J; Keller TH; Hung AW
J Med Chem; 2020 Jan; 63(2):621-637. PubMed ID: 31910010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
